GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: August 28, 2003, 18:21:02 ; Search time 18.5455 Seconds
(without alignments)
51.353 Million cell updates/sec

Title: US-09-743-225-1
Perfect score: 30
Sequence: 1 LKTPRV 6

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	30	100.0	6	21	AAB17988	Beta-2GPI Ab bindi
2	30	100.0	6	21	AAY69266	Peptide which inhi
3	30	100.0	6	23	ABB73359	Exemplary pharmaco
4	30	100.0	8	21	AAB17989	Beta-2GPI Ab bindi
5	30	100.0	8	23	ABB73360	Exemplary pharmaco
6	30	100.0	10	21	AAY69268	Peptide which inhi
7	30	100.0	11	21	AAB17990	Beta-2GPI Ab bindi
8	30	100.0	11	23	ABB73361	Exemplary pharmaco
9	30	100.0	12	21	AAY69259	Monopeptide which
10	30	100.0	216	22	AAG74046	Human colon cancer
11	30	100.0	216	24	ABU04924	Human expressed pr
12	30	100.0	240	21	AAB23166	Human colorectal c
13	30	100.0	257	22	AAU18689	Renal and cardiova
14	30	100.0	257	22	AAU17047	Human novel secret
15	30	100.0	257	22	AAU20472	Human secreted pro
16	30	100.0	257	24	ABU04926	Human expressed pr
17	30	100.0	257	24	ABU04927	Human expressed pr
18	30	100.0	257	24	ABU04928	Human expressed pr
19	30	100.0	317	22	AAM25633	Human protein sequ
20	30	100.0	405	24	ABU04916	Human expressed pr
21	30	100.0	405	24	ABU04937	Human expressed pr
22	30	100.0	406	23	AAG79358	CJA8 sequence. Ho
23	30	100.0	420	24	ABU56625	Lung cancer-associ
24	30	100.0	423	22	AAE06944	Human transmembran
25	30	100.0	423	24	ABG72428	Human colorectal c
26	30	100.0	423	24	ABU04918	Human expressed pr
27	30	100.0	423	24	ABU04919	Human expressed pr
28	30	100.0	423	24	ABU04923	Human expressed pr
29	30	100.0	428	23	ABG96430	Human ovarian canc
30	30	100.0	432	21	AAY99417	Human PRO1570 (UNQ
31	30	100.0	432	22	AAU29188	Human PRO polypept
32	30	100.0	432	22	AAB87581	Human PRO1570. Ho
33	30	100.0	432	22	AAB66166	Protein of the inv
34	30	100.0	432	23	ABG95906	Human secreted/tra
35	30	100.0	432	23	AAU76535	Tumour-associated
36	30	100.0	432	24	ABU71276	Human PRO1570 prot
37	30	100.0	432	24	ABU71561	Human secreted pol
38	30	100.0	432	24	ABU72007	Novel human secret
39	30	100.0	432	24	ABU72164	Human PRO polypept
40	30	100.0	432	24	ABU65733	Human secreted/tra
41	30	100.0	432	24	ABU66066	Novel human secret
42	30	100.0	432	24	ABU67570	Human secreted/tra
43	30	100.0	432	24	ABU65428	Human PRO polypept
44	30	100.0	432	24	ABU58564	Human PRO polypept
45	30	100.0	432	24	ABU56100	Human secreted/tra

ALIGNMENTS

RESULT 1
AAB17988
ID AAB17988 standard; Peptide; 6 AA.
XX
AC AAB17988;
XX
DT 31-OCT-2000 (first entry)
XX
DE Beta-2GPI Ab binding peptide sequence SEQ ID NO:1100.
XX
KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW vascular endothelial growth factor; matrix metalloproteinase;
KW asthma; thrombosis; pharmaceutical.
XX
OS Synthetic.
XX
PN WO200024782-A2.
XX
PD 04-MAY-2000.
XX
PF 25-OCT-1999; 99WO-US25044.
XX
PR 23-OCT-1998; 98US-0105371.
PR 22-OCT-1999; 99US-0428082.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham J, Boone TC;

XX
DR WPI; 2000-350702/30.
XX
PT Novel composition of matter comprising an Fc domain and
PT pharmacologically active peptides, useful for treating cancer and
PT autoimmune diseases -
XX
PS Claim 39; Page 599; 608pp; English.
XX
CC The present invention describes composition of matter (I) comprising an
CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC where P1, P2, P3, and P4 = are each independently sequences of
CC pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC independently linkers; and a, b, c, d, e, and f = are each independently
CC 0 or 1, provided that at least 1 of a and b is 1. The composition can
CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC activities. DNAs, vectors and host cells from the present invention can
CC be used for producing pharmaceutical compositions. The compositions are
CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC The use of an Fc domain (rather than a Fab domain) can provide a longer
CC half-life or incorporate functions such as Fc receptor binding, protein
CC A binding, complement fixation, and possibly placental transfer. AAA69443
CC to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC sequences used in the exemplification of the present invention.
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 30; DB 21; Length 6;
Best Local Similarity 100.0%; Pred. No. 9.3e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 1 LKTPRV 6

RESULT 2
AAY69266
ID AAY69266 standard; peptide; 6 AA.
XX
AC AAY69266;
XX
DT 30-MAY-2000 (first entry)
XX
DE Peptide which inhibits anti-beta-2-glycoprotein 1 antibodies.
XX
KW Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;
KW anti-phospholipid syndrome; anti-phospholipid antibody;
KW pregnancy complication; thrombosis; coagulation dysregulation.
XX
OS Synthetic.
XX
PN WO200001729-A2.
XX
PD 13-JAN-2000.
XX
PF 06-JUL-1999; 99WO-IL00366.
XX
PR 07-JUL-1998; 98IL-0125262.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;
XX
DR WPI; 2000-182105/16.
XX
PT Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1
PT antibodies, useful for diagnosis and treatment of anti-phospholipid
PT syndrome in humans -
XX
PS Claim 3; Page 37; 58pp; English.
XX
CC The present sequence represents a synthetic peptide which is capable
CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1
CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo
CC induction of experimental anti-phospholipid syndrome in mice by
CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis
CC and treatment of anti-phospholipid syndrome. They may also be used
CC for the diagnosis of anti-phospholipid antibodies with different
CC pathogenic biofunctions which may correlate with either pregnancy
CC complications, thrombosis or coagulation dysregulation.
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 30; DB 21; Length 6;
Best Local Similarity 100.0%; Pred. No. 9.3e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 1 LKTPRV 6

RESULT 3
ABB73359
ID ABB73359 standard; Peptide; 6 AA.
XX
AC ABB73359;
XX
DT 05-APR-2002 (first entry)
XX
DE Exemplary pharmacologically active peptide SEQ ID NO:1098.
XX
KW Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
KW antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW sleep disorder; neurological degenerative disease; anaemia;
KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
KW Fanconi's syndrome.
XX
OS Synthetic.
XX
PN WO200183525-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US14310.
XX
PR 03-MAY-2000; 2000US-0563286.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
XX
DR WPI; 2002-130313/17.
XX
PT Novel vehicle-peptide molecule or its multimers useful for treating
PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
PT diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS Claim 39; Page 62; 176pp; English.
XX
CC The present invention describes a vehicle-peptide molecule (I) or its
CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
CC antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC neuroprotective activities. (I) can be used as a therapeutic or

CC prophylactic agent as well as for screening purposes. (I) is useful for
CC diagnosing diseases characterised by dysfunction of their associated
CC protein of interest, for identifying normal or abnormal proteins of
CC interest, as a part of diagnostic kit to detect the presence of their
CC proteins of interest in a biological sample. Additionally, (I) is useful
CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,
CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC infertility, and neurological degenerative diseases. (I), comprising
CC EPO-mimetic compounds are useful for treating disorders characterised by
CC low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC compounds are useful for treating conditions that involve an existing
CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC represent amino acid and nucleic acid sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 30; DB 23; Length 6;
Best Local Similarity 100.0%; Pred. No. 9.3e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 1 LKTPRV 6

RESULT 4
AAB17989
ID AAB17989 standard; Peptide; 8 AA.
XX
AC AAB17989;
XX
DT 31-OCT-2000 (first entry)
XX
DE Beta-2GPI Ab binding peptide sequence SEQ ID NO:1101.
XX
KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW vascular endothelial growth factor; matrix metalloproteinase;
KW asthma; thrombosis; pharmaceutical.
XX
OS Synthetic.
XX
PN WO200024782-A2.
XX
PD 04-MAY-2000.
XX
PF 25-OCT-1999; 99WO-US25044.
XX
PR 23-OCT-1998; 98US-0105371.
PR 22-OCT-1999; 99US-0428082.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham J, Boone TC;
XX
DR WPI; 2000-350702/30.
XX
PT Novel composition of matter comprising an Fc domain and
PT pharmacologically active peptides, useful for treating cancer and
PT autoimmune diseases -
XX
PS Claim 39; Page 599; 608pp; English.
XX
CC The present invention describes composition of matter (I) comprising an
CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC where P1, P2, P3, and P4 = are each independently sequences of
CC pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC independently linkers; and a, b, c, d, e, and f = are each independently
CC 0 or 1, provided that at least 1 of a and b is 1. The composition can
CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC activities. DNAs, vectors and host cells from the present invention can
CC be used for producing pharmaceutical compositions. The compositions are
CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC The use of an Fc domain (rather than a Fab domain) can provide a longer
CC half-life or incorporate functions such as Fc receptor binding, protein
CC A binding, complement fixation, and possibly placental transfer. AAA69443
CC to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC sequences used in the exemplification of the present invention.
XX
SQ Sequence 8 AA;

Query Match 100.0%; Score 30; DB 21; Length 8;
Best Local Similarity 100.0%; Pred. No. 9.3e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 3 LKTPRV 8

RESULT 5
ABB73360
ID ABB73360 standard; Peptide; 8 AA.
XX
AC ABB73360;
XX
DT 05-APR-2002 (first entry)
XX
DE Exemplary pharmacologically active peptide SEQ ID NO:1099.
XX
KW Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
KW antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW sleep disorder; neurological degenerative disease; anaemia;
KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
KW Fanconi's syndrome.
XX
OS Synthetic.
XX
PN WO200183525-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US14310.
XX
PR 03-MAY-2000; 2000US-0563286.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
XX
DR WPI; 2002-130313/17.
XX
PT Novel vehicle-peptide molecule or its multimers useful for treating
PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
PT diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS Claim 39; Page 62; 176pp; English.
XX
CC The present invention describes a vehicle-peptide molecule (I) or its

CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive, cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological, antianaemic, anorectic, antiinfertility, haemostatic, dermatological and neuroprotective activities. (I) can be used as a therapeutic or prophylactic agent as well as for screening purposes. (I) is useful for diagnosing diseases characterised by dysfunction of their associated protein of interest, for identifying normal or abnormal proteins of interest, as a part of diagnostic kit to detect the presence of their proteins of interest in a biological sample. Additionally, (I) is useful for treating inflammatory and autoimmune diseases, tumour growth, cancer, rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders, infertility, and neurological degenerative diseases. (I), comprising EPO-mimetic compounds are useful for treating disorders characterised by low red blood cell levels such as anaemia. The TPO-mimetic comprising compounds are useful for treating conditions that involve an existing megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic tumour which result in thrombocytopaenia, systemic lupus erythematosus, and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777 represent amino acid and nucleic acid sequences used in the exemplification of the present invention.
XX
SQ Sequence 8 AA;

Query Match 100.0%; Score 30; DB 23; Length 8;
Best Local Similarity 100.0%; Pred. No. 9.3e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 3 LKTPRV 8

RESULT 6
AAY69268
ID AAY69268 standard; peptide; 10 AA.
XX
AC AAY69268;
XX
DT 30-MAY-2000 (first entry)
XX
DE Peptide which inhibits anti-beta-2-glycoprotein 1 antibodies.
XX
KW Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;
KW anti-phospholipid syndrome; anti-phospholipid antibody;
KW pregnancy complication; thrombosis; coagulation dysregulation.
XX
OS Synthetic.
XX
PN WO200001729-A2.
XX
PD 13-JAN-2000.
XX
PF 06-JUL-1999; 99WO-IL00366.
XX
PR 07-JUL-1998; 98IL-0125262.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;
XX
DR WPI; 2000-182105/16.
XX
PT Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1
PT antibodies, useful for diagnosis and treatment of anti-phospholipid
PT syndrome in humans -
XX
PS Claim 3; Page 37; 58pp; English.
XX
CC The present sequence represents a synthetic peptide which is capable
CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1
CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo
CC induction of experimental anti-phospholipid syndrome in mice by
CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis
CC and treatment of anti-phospholipid syndrome. They may also be used
CC for the diagnosis of anti-phospholipid antibodies with different
CC pathogenic biofunctions which may correlate with either pregnancy
CC complications, thrombosis or coagulation dysregulation.
XX
SQ Sequence 10 AA;

Query Match 100.0%; Score 30; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 3.2;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 3 LKTPRV 8

RESULT 7
AAB17990
ID AAB17990 standard; Peptide; 11 AA.
XX
AC AAB17990;
XX
DT 31-OCT-2000 (first entry)
XX
DE Beta-2GPI Ab binding peptide sequence SEQ ID NO:1102.
XX
KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW vascular endothelial growth factor; matrix metalloproteinase;
KW asthma; thrombosis; pharmaceutical.
XX
OS Synthetic.
XX
PN WO200024782-A2.
XX
PD 04-MAY-2000.
XX
PF 25-OCT-1999; 99WO-US25044.
XX
PR 23-OCT-1998; 98US-0105371.
PR 22-OCT-1999; 99US-0428082.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham J, Boone TC;
XX
DR WPI; 2000-350702/30.
XX
PT Novel composition of matter comprising an Fc domain and
PT pharmacologically active peptides, useful for treating cancer and
PT autoimmune diseases -
XX
PS Claim 39; Page 599; 608pp; English.
XX
CC The present invention describes composition of matter (I) comprising an
CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC where P1, P2, P3, and P4 = are each independently sequences of
CC pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC independently linkers; and a, b, c, d, e, and f = are each independently
CC 0 or 1, provided that at least 1 of a and b is 1. The composition can
CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC activities. DNAs, vectors and host cells from the present invention can
CC be used for producing pharmaceutical compositions. The compositions are
CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC The use of an Fc domain (rather than a Fab domain) can provide a longer
CC half-life or incorporate functions such as Fc receptor binding, protein

CC A binding, complement fixation, and possibly placental transfer. AAA69443
CC to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC sequences used in the exemplification of the present invention.
XX
SQ Sequence 11 AA;

Query Match 100.0%; Score 30; DB 21; Length 11;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 3 LKTPRV 8

RESULT 8
ABB73361
ID ABB73361 standard; Peptide; 11 AA.
XX
AC ABB73361;
XX
DT 05-APR-2002 (first entry)
XX
DE Exemplary pharmacologically active peptide SEQ ID NO:1100.
XX
KW Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
KW antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW sleep disorder; neurological degenerative disease; anaemia;
KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
KW Fanconi's syndrome.
XX
OS Synthetic.
XX
PN WO200183525-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US14310.
XX
PR 03-MAY-2000; 2000US-0563286.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
XX
DR WPI; 2002-130313/17.
XX
PT Novel vehicle-peptide molecule or its multimers useful for treating
PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
PT diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS Claim 39; Page 62; 176pp; English.
XX
CC The present invention describes a vehicle-peptide molecule (I) or its
CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
CC antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC neuroprotective activities. (I) can be used as a therapeutic or
CC prophylactic agent as well as for screening purposes. (I) is useful for
CC diagnosing diseases characterised by dysfunction of their associated
CC protein of interest, for identifying normal or abnormal proteins of
CC interest, as a part of diagnostic kit to detect the presence of their
CC proteins of interest in a biological sample. Additionally, (I) is useful
CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,
CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC infertility, and neurological degenerative diseases. (I), comprising
CC EPO-mimetic compounds are useful for treating disorders characterised by
CC low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC compounds are useful for treating conditions that involve an existing
CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC represent amino acid and nucleic acid sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 11 AA;

Query Match 100.0%; Score 30; DB 23; Length 11;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 3 LKTPRV 8

RESULT 9
AAY69259
ID AAY69259 standard; peptide; 12 AA.
XX
AC AAY69259;
XX
DT 30-MAY-2000 (first entry)
XX
DE Monopeptide which inhibits anti-beta-2-glycoprotein 1 antibodies.
XX
KW Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;
KW anti-phospholipid syndrome; anti-phospholipid antibody;
KW pregnancy complication; thrombosis; coagulation dysregulation.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 11
FT /note= "FmocLys(Fmoc)-OH"
XX
PN WO200001729-A2.
XX
PD 13-JAN-2000.
XX
PF 06-JUL-1999; 99WO-IL00366.
XX
PR 07-JUL-1998; 98IL-0125262.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;
XX
DR WPI; 2000-182105/16.
XX
PT Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1
PT antibodies, useful for diagnosis and treatment of anti-phospholipid
PT syndrome in humans -
XX
PS Disclosure; Page 13; 58pp; English.
XX
CC The present sequence represents a synthetic peptide which is capable
CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1
CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo
CC induction of experimental anti-phospholipid syndrome in mice by
CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis
CC and treatment of anti-phospholipid syndrome. They may also be used
CC for the diagnosis of anti-phospholipid antibodies with different
CC pathogenic biofunctions which may correlate with either pregnancy
CC complications, thrombosis or coagulation dysregulation.
XX
SQ Sequence 12 AA;

```
  Query Match           100.0%;  Score 30;  DB 21;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 3.8;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 LKTPRV 6
            ||||||
Db        3 LKTPRV 8


RESULT 10
AAG74046
ID   AAG74046 standard; Protein; 216 AA.
XX
AC   AAG74046;
XX
DT   03-SEP-2001  (first entry)
XX
DE   Human colon cancer antigen protein SEQ ID NO:4810.
XX
KW   Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW   colorectal carcinoma.
XX
OS   Homo sapiens.
XX
PN   WO200122920-A2.
XX
PD   05-APR-2001.
XX
PF   28-SEP-2000; 2000WO-US26524.
XX
PR   29-SEP-1999;   99US-0157137.
PR   03-NOV-1999;   99US-0163280.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Barash SC,  Birse CE,  Rosen CA;
XX
DR   WPI; 2001-235357/24.
DR   N-PSDB; AAH33477.
XX
PT   Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
PT   useful for preventing, diagnosing and/or treating colorectal cancers -
XX
PS   Claim 11; Page 6595-6596; 9803pp; English.
XX
CC   AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
CC   cancer-associated nucleic acid molecules (N) and proteins (P), where
CC   the proteins are collectively known as colon cancer antigens. The colon
CC   cancer antigens have cytostatic activity and can be used in gene
CC   therapy and vaccine production. N and P may be used in the prevention,
CC   diagnosis and treatment of diseases associated with inappropriate P
CC   expression. For example, N and P may be used to treat disorders
CC   associated with decreased expression by rectifying mutations or deletions
CC   in a patient's genome that affect the activity of P by expressing
CC   inactive proteins or to supplement the patients own production of P.
CC   Additionally, N may be used to produce the colon cancer-associated Ps,
CC   by inserting the nucleic acids into a host cell and culturing the cell
CC   to express the proteins. N and P can be used in the prevention, diagnosis
CC   and treatment of colorectal carcinomas and cancers. AAH37196 to AAH37204
CC   and AAB77789 represent sequences used in the exemplification of the
CC   present invention.
CC   N.B. Pages 666 to 682 and page 7053 of the sequence listing were
CC   missing at time of publication, meaning no sequences are present for
CC   SEQ ID NO:1027 to 1052, 7921 and 7922.
XX
SQ   Sequence   216 AA;

  Query Match           100.0%;  Score 30;  DB 22;  Length 216;
  Best Local Similarity  100.0%;  Pred. No. 77;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 LKTPRV 6
            ||||||
Db      190 LKTPRV 195


RESULT 11
ABU04924
ID   ABU04924 standard; Protein; 216 AA.
XX
AC   ABU04924;
XX
DT   29-JAN-2003  (first entry)
XX
DE   Human expressed protein tag (EPT) #1590.
XX
KW   Translational profiling; expressed protein tag; EPT; kinase;
KW   phosphatase; protease; protease inhibitor; transporter;
KW   cytoskeletal protein; receptor; transcription factor; cancer; MHC;
KW   major histocompatability complex; myeloma; colon cancer;
KW   gastric cancer; adenocarcinoma; sarcoma; melanoma; lymphoma;
KW   leukaemia.
XX
OS   Homo sapiens.
XX
PN   WO200278524-A2.
XX
PD   10-OCT-2002.
XX
PF   28-MAR-2002; 2002WO-US09671.
XX
PR   28-MAR-2001; 2001US-279495P.
PR   21-MAY-2001; 2001US-292544P.
PR   08-AUG-2001; 2001US-310801P.
PR   01-OCT-2001; 2001US-326370P.
PR   04-DEC-2001; 2001US-336780P.
PR   20-FEB-2002; 2002US-358985P.
XX
PA   (ZYCO-) ZYCOS INC.
XX
PI   Chicz RM,  Tomlinson AJ,  Urban RG;
XX
DR   WPI; 2003-040607/03.
XX
PT   New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT   cytoskeletal proteins, receptors or transcription factors), useful for
PT   treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma
PT   or leukemia  -
XX
PS   Example 2; SEQ ID No 1590; 134pp; English.
XX
CC   The invention describes a purified polypeptide, which comprises a
CC   fragment of a kinase, phosphatase, protease, protease inhibitor,
CC   transporter, cytoskeletal protein, receptor or transcription factor.
CC   The polypeptide is useful as an immunogenic composition for eliciting
CC   in a mammal an immunogenic response directed against any of the purified
CC   polypeptide. The purified polypeptide, or the antibody that binds to
CC   this polypeptide, is useful for treating cancer. The polypeptide is
CC   also useful for identifying compounds that binds to a naturally
CC   processed class I or class II MHC-binding polypeptide. The polypeptides
CC   and polynucleotides are particularly useful for treating or preventing
CC   myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC   lymphoma or leukaemia. These are also useful for screening agents for
CC   treating the above mentioned diseases. This sequence represents an
CC   expressed protein tag (EPT) isolated from human tissue for translational
CC   profiling.
CC   Note: This sequence does not appear in the printed specification but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   216 AA;

  Query Match           100.0%;  Score 30;  DB 24;  Length 216;
  Best Local Similarity  100.0%;  Pred. No. 77;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 LKTPRV 6
              ||||||
Db        190 LKTPRV 195
```

RESULT 12
AAB23166
ID AAB23166 standard; Protein; 240 AA.
XX
AC AAB23166;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human colorectal cancer modulator protein CJA8, C-terminal portion.
XX
KW Colorectal cancer modulator protein; CCMP; human; expression profile;
KW drug screening; diagnosis; prognosis; antibody; vaccine; CJA8;
KW immunogenic; gene therapy; targetting moiety; CCMP inhibitor; tumour;
KW chromosome 11.
XX
OS Homo sapiens.
XX
PN WO200055633-A2.
XX
PD 21-SEP-2000.
XX
PF 15-MAR-2000; 2000WO-US07044.
XX
PR 15-MAR-1999; 99US-0268866.
PR 09-NOV-1999; 99US-0435945.
PR 09-NOV-1999; 99US-0436983.
PR 29-NOV-1999; 99US-0450857.
PR 02-DEC-1999; 99US-0453850.
PR 28-JAN-2000; 2000US-0493444.
XX
PA (EOSB-) EOS BIOTECHNOLOGY INC.
XX
PI Mack D, Gish KC, Wilson KE;
XX
DR WPI; 2000-638217/61.
DR N-PSDB; AAA97361.
XX
PT Use of expression profiles, nucleic acids and proteins involved in
PT colorectal cancer for diagnosis and prognosis of colorectal cancer and
PT identifying candidate agent and/or targets which modulate colorectal
PT cancer -
XX
PS Claim 1; Page -; 308pp; English.
XX
CC The invention relates to the use of expression profile nucleic acids
CC encoding colorectal cancer modulator proteins (CCMPs) for screening
CC drug candidates and bioactive agents capable of binding and/or
CC modulating CCMPs; for evaluating the effect of drugs for the treatment of
CC colorectal cancer; for the diagnosis and prognosis of colorectal cancer;
CC and as a target for colorectal cancer therapy. The expression profile
CC nucleic acids used in the methods of the invention encode the CCMPs CZA8,
CC BCX2, CBC2, CBC1, CBC3, CJA8, CJA9, CGA7, BCN5, CQA1, BCN7, CQA2, CAA2,
CC CAA9 and CGA8. The CCMPs (especially CJA8 (AAB23166)) may be used in
CC vaccine compositions, and also to raise antibodies for use as therapeutic
CC agents, or targetting moieties for therapeutic agents in the treatment
CC of colorectal cancer. Inhibitors of CCMP activity may also be used in
CC the treatment of other tumours. CCMP nucleotides, especially those
CC encoding CJA8, may be used in gene therapy, and in genetic vaccines. The
CC present sequence represents the colorectal cancer modulator protein
CC CJA8. Note: The CJA8 protein sequence disclosed in figure 36 is
CC illegible. This sequence is obtained by decoding the the portion of the
CC CJA8 cDNA that is legible in figure 35.
XX
SQ Sequence 240 AA;

```
  Query Match             100.0%;  Score 30;  DB 21;  Length 240;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 LKTPRV 6
              ||||||
Db          3 LKTPRV 8
```

RESULT 13
AAU18689
ID AAU18689 standard; Protein; 257 AA.
XX
AC AAU18689;
XX
DT 21-NOV-2001 (first entry)
XX
DE Renal and cardiovascular-associated protein, Seq ID 128.
XX
KW Human; antiinflammatory; neuroprotective; immunomodulator; vulnerary;
KW cardiovascular; cytostatic; nephrotropic; antianaemic; nephritis;
KW immunosuppressive; kidney disorder; renal failure; hypertension;
KW cardiovascular disorder; myocardial infarction; blood disorder; anaemia;
KW blood coagulation disorder; electrolyte imbalance disorder; cancer;
KW hyponatraemia; hyperkalaemia; neoplastic disorder; nephtoma;
KW autoimmune disease; inflammatory disease; reproductive system disorder;
KW endocrine disorder; neural activity; neurological disorder;
KW wound healing; respiratory disorder.
XX
OS Homo sapiens.
XX
PN WO200155328-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01359.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.

PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488787/53.
DR N-PSDB; AAS30210.
XX
PT New polynucleotides and polypeptides, useful for diagnosing, treating,
PT preventing or prognosing e.g. kidney, cardiovascular, blood,
PT electrolyte imbalance or neoplastic disorders, autoimmune diseases,
PT cancers -
XX
PS Claim 1; SEQ ID No 128; 506pp; English.
XX
CC The invention relates to novel nucleic acids and polypeptides useful for
CC diagnosing, treating, preventing and/or prognosing disorders related to
CC these polypeptides. The polynucleotides are especially useful in the
CC diagnosis, prognosis, prevention and/or treatment of diseases which
CC include kidney disorders (e.g. renal failure or nephritis),
CC cardiovascular disorders (e.g. hypertension or myocardial infarction),
CC blood disorders (e.g. anaemia or blood coagulation disorders),
CC electrolyte imbalance disorders (e.g. hyponatraemia or hyperkalaemia),
CC neoplastic disorders (e.g. nephtoma or renal cell cancer), autoimmune
CC diseases, cancers, inflammatory diseases, reproductive system
CC disorders, endocrine disorders, neural activity and neurological
CC disorders, wound healing and respiratory disorders. AAU18644-AAU18715
CC represent the novel human renal and cardiovascular-associated amino
CC acid sequences of the invention. Note: The sequence data for this patent
CC did not form part of the printed specification, but was obtained in
CC electronic format directly from WIPO at:
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 257 AA;

Query Match 100.0%; Score 30; DB 22; Length 257;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 227 LKTPRV 232

RESULT 14
AAU17047
ID AAU17047 standard; Protein; 257 AA.
XX
AC AAU17047;

XX
DT 07-NOV-2001 (first entry)
XX
DE Human novel secreted protein, SEQ ID 288.
XX
KW Human; immunosuppressive; antiarthritic; antirheumatic;
KW cytostatic; cardiant; vasotropic; cerebroprotective; nootropic;
KW neuroprotective; antibacterial; virucide; fungicide; opthalmalogical;
KW vulnerary; secreted protein; rheumatoid arthritis;
KW hyperproliferative disorder; cardiovascular disorder; cardiac arrest;
KW cerebrovascular disorder; cerebral ischaemia; angiogenesis;
KW nervous system disorder; Alzheimer's disease; infection; ocular disorder;
KW corneal infection; wound healing; epithelial cell proliferation;
KW skin ageing; food additive; preservative; antiproliferative.
XX
OS Homo sapiens.
XX
PN WO200155441-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01320.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.

PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476222/51.
DR N-PSDB; AAS26952.
XX
PT Novel polypeptides and polynucleotides useful as diagnostic reagents to
PT diagnose diseases or disorders associated with aberrant expression or
PT activity of polypeptides, for treating blood clotting disorder,
PT haemophilia -
XX
PS Claim 11; SEQ ID No 288; 601pp; English.
XX
CC The invention relates to isolated nucleic acid molecules and their
CC encoded secreted proteins. The nucleic acids and proteins are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They
CC are also used in diagnosing a pathological condition or susceptibility
CC to a pathological condition. Antibodies to the proteins can also
CC be used in alleviating symptoms associated with the disorders and in
CC diagnostic immunoassays e.g. radioimmunoassays or enzyme linked
CC immunosorbant assays (ELISA). Disorders which are diagnosed or treated
CC include autoimmune diseases e.g. rheumatoid arthritis,
CC hyperproliferative disorders e.g. neoplasms of the breast or liver,
CC cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders
CC e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.
CC Alzheimer's disease, infections caused by bacteria, viruses and fungi
CC and ocular disorders e.g. corneal infection, and many other
CC disorders listed in the specification. The polypeptides can also
CC be used to aid wound healing and epithelial cell proliferation, to
CC prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present

Query Match 100.0%; Score 30; DB 22; Length 257;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 227 LKTPRV 232

RESULT 15
AAU20472
ID AAU20472 standard; Protein; 257 AA.
XX
AC AAU20472;
XX
DT 06-DEC-2001 (first entry)
XX
DE Human secreted protein, Seq ID No 464.
XX
KW Immunomodulatory; human immunodeficiency virus; HIV; anaemia; angina;
KW rheumatoid arthritis; antiarteriosclerotic; cardiant; vascular;
KW cerebroprotective; thrombolytic; antimicrobial; ophthalmological;
KW cytostatic; Alzheimer's disease; Parkinson's disease; human; cancer;
KW multiple sclerosis; cancer; hyperproliferative disorder; infection;
KW Gaucher's disease; neurological disease; cerebrovascular disorder;
KW thrombosis; wound healing.
XX
OS Homo sapiens.
XX
PN WO200155326-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01347.
XX
PR 31-JAN-2000; 2000US-0179065.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-451931/48.
DR N-PSDB; AAS33181.
XX
PT New nucleic acids and polypeptides, useful for diagnosing, preventing
PT or treating medical conditions -
XX
PS Claim 11; SEQ ID No 464; 753pp; English.
XX
CC The invention relates to novel isolated nucleic acid molecules (I)
CC encoding human secreted proteins (II). (I) and (II) are used to prevent,
CC treat or ameliorate a medical condition in e.g. humans, mice, rabbits,
CC goats, horses, cats, dogs, chickens or sheep. (I) and (II) may be used in
CC the prevention, treatment and diagnosis of diseases associated with
CC inappropriate expression of secreted proteins. (I) and complementary
CC sequences may also be used as DNA probes in diagnostic assays (e.g.
CC polymerase chain reactions (PCR)) to detect and quantitate the presence
CC of similar nucleic acid sequences in samples, and so which patients may
CC be in need of restorative therapy. (II) may also be used as antigens in
CC the production of antibodies and in assays to identify modulators
CC (agonists and antagonists) of the expression and activity of the secreted
CC proteins. The anti-(II) antibodies and antagonists may also be used to
CC down regulate expression and activity of (II). The anti-(II) antibodies
CC may also be used as diagnostic agents for detecting the presence of (II)
CC in samples (e.g. by enzyme linked immunosorbant assay (ELISA)). The
CC disorders include for example: immune/autoimmune diseases (e.g. HIV
CC (human immunodeficiency virus) infections, anaemia, rheumatoid arthritis
CC and multiple sclerosis), cancers and hyperproliferative disorders (e.g.
CC melanomas, neoplasms of the breast or liver, Sezary syndrome and
CC Gaucher's disease), neurological diseases (e.g. Alzheimer's disease,
CC Parkinson's disease and Charcot-Marie-Tooth disease), cardio-/
CC cerebrovascular disorders (e.g. cardiac arrest, tachycardia,
CC angina and thrombosis), infections caused by bacteria, viruses and
CC fungi and ocular disorders (e.g. corneal infections). (I) and (II),
CC agonists, antagonists and antibodies can also be used to promote wound
CC healing, maintain organs before transplantation, and support cell culture
CC of primary tissues. AAU20342-AAU20666 represent human secreted protein
CC amino acid sequences, and related sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification but was obtained in electronic format directly from WIPO
CC at: ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 257 AA;

Query Match 100.0%; Score 30; DB 22; Length 257;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKTPRV 6
||||||
Db 227 LKTPRV 232

Search completed: August 28, 2003, 18:34:25

Job time : 19.5455 secs